COVID-19 Treatment Provider Update

Indiana Department of Health

February 4, 2022

COVID-19 Therapeutics Available for COVID-19 Patients at Risk for Progression to Severe Disease

Several therapeutics are now available to prescribe to your patients at high risk for disease progression:

- GSK's sotrovimab monoclonal antibody infusion
- Merck's oral antiviral molnupiravir, which reports a 30% reduction in hospitalization
- Pfizer's oral antiviral paxlovid, which reports reducing the risk of hospitalization or death by 89%
- Veklury (remdesivir) given as a 3-day outpatient infusion, which in a study resulted in an 87% lower risk of hospitalization or death than placebo.

While vaccination is still the best way to prevent serious COVID-19 infections, please review the EUAs, treatment recommendations, prescribing information, and local distribution locations and begin to prescribe these to your patients. Indiana is still receiving limited allocations of these therapeutics. Healthcare providers should consult the NIH panel's COVID-19 treatment guidelines and assess whether these treatments are right for their patients. IDOH has worked to ensure that these medications are available across the state, and we will continue to add locations.

The Indiana Department of Health has posted online an updated map of COVID-19 treatment sites (right) showing where they are available.



Please refer to the **Therapeutics Decision Guide** and the **Side-by-Side Overview of Outpatient Therapies** from the U.S. Department of Health and Human Services for details and fact sheets. A sample **Outpatient COVID-19 Therapy Patient Checklist** is also attached as a referral form example.

Monoclonal Antibody Infusion Update: The only mAb infusion effective against the Omicron variant is GSK's sotrovimab. Allocations of Bamlanivimab/Etesevimab and Regeneron therapeutics have been paused. Providers should stop prescribing Regeneron and Bamlanivimab/Etesevimab infusions at this time, as there is no expected benefit but a risk of side effects remains.

Veklury (remdesivir) Update: The FDA has expanded the approved indication for Veklury to include its use in adults and pediatric patients (12 years of age and older who weigh at least 40 kilograms, which is about 88 pounds) with positive results of direct SARS-CoV-2 viral testing, and who are not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

The agency also revised the EUA for Veklury to additionally authorize the drug for treatment of pediatric patients weighing 3.5 kilograms to less than 40 kilograms or pediatric patients less than 12 years of age weighing at least 3.5 kilograms, with positive results of direct SARS-CoV-2 viral testing, and who are not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.